Want to see CARM full AI Analyst Report?
Carisma Therapeutics (CARM) AI Stock Analysis
Top Page
Carisma Therapeutics
(Other OTC:CARM)
The score is driven primarily by very weak financial performance (persistent losses, heavy cash burn, and negative equity) and materially negative corporate events (Nasdaq delisting and wind-down). Technicals also reflect a sustained downtrend, while valuation looks optically low but is not supportive given the financial and operational pressures.
Carisma Therapeutics (CARM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $20.92K
- Dividend Yield
- ―
- Average Volume (3M)
- 1,220
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- 7.12
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 46
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Carisma Therapeutics Business Overview & Revenue Model
Company Description
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of li...
How the Company Makes Money
Carisma Therapeutics generates revenue primarily through a combination of research and development funding, partnerships, and potential future product sales. The company may enter into collaborations with larger pharmaceutical firms that provide upfr...
Carisma Therapeutics Financial Statement Overview
Summary
Financial health is very weak: revenue is down sharply (TTM -31.4%), operating profitability remains deeply negative across multiple years, and cash burn is severe with deeply negative TTM operating cash flow and free cash flow (~-$22.4M). Balance-sheet risk is elevated due to negative stockholders’ equity and a shrinking asset base, despite low absolute debt.
Income Statement
24NegativeBalance Sheet
28NegativeCash Flow
18Very Negative| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.63M | 19.63M | 14.92M | 9.83M | 26.54M | 11.24M |
| Gross Profit | 51.61M | -40.04M | -59.21M | 9.83M | 26.46M | 11.24M |
| EBITDA | 13.66M | -56.83M | -85.89M | -51.99M | -7.93M | -27.93M |
| Net Income | 8.04M | -60.48M | -86.88M | -61.23M | -336.00K | -28.35M |
Balance Sheet | ||||||
| Total Assets | 6.55M | 30.46M | 89.55M | 72.15M | 312.60M | 188.45M |
| Cash, Cash Equivalents and Short-Term Investments | 2.78M | 18.83M | 77.61M | 52.00M | 162.64M | 55.39M |
| Total Debt | 762.00K | 2.48M | 3.12M | 40.16M | 2.63M | 0 |
| Total Liabilities | 7.42M | 58.37M | 63.02M | 214.82M | 140.89M | 197.68M |
| Stockholders Equity | -867.00K | -27.91M | 26.53M | -157.06M | 171.71M | -9.23M |
Cash Flow | ||||||
| Free Cash Flow | -22.41M | -60.04M | -82.31M | -12.23M | -39.20M | -27.45M |
| Operating Cash Flow | -22.41M | -59.92M | -81.18M | -7.57M | -37.33M | -27.01M |
| Investing Cash Flow | 687.00K | -123.00K | 72.41M | -32.56M | -1.87M | -440.00K |
| Financing Cash Flow | -2.38M | 344.00K | 62.18M | 35.77M | 15.96M | 72.26M |
Carisma Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CARM, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 10.65 is Positive, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CARM.
Carisma Therapeutics Risk Analysis
Carisma Therapeutics disclosed 82 risk factors in its most recent earnings report. Carisma Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
2 New RisksCarisma Therapeutics Peers Comparison
Overall Rating
GTBP42Neutral- CARM40Underperform
AIM40Underperform
BOLT40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GTBP | 42Neutral | $10.96M | -0.05 | -443.08% | ― | ― | 75.09% |
| CARM | 40Underperform | $20.92K | 0.00 | -149.10% | ― | ― | ― |
| AIM | 40Underperform | $6.16M | -0.04 | 952.76% | ― | -21.49% | 84.62% |
| BOLT | 40Underperform | $12.69M | -0.41 | -126.23% | ― | 12.79% | 37.93% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CARM | Carisma Therapeutics, Inc. | 0.02 | -0.03 | -60.00% | |
| AIM | Aim Immunotech Inc. | 0.15 | -1.85 | -92.33% | |
| GTBP | Gt Biopharma, Inc. | 5.32 | -10.26 | -65.85% | |
| BOLT | Bolt Biotherapeutics, Inc. | 6.59 | 1.01 | 18.10% | |
| CERO | Cero Therapeutics Holdings, Inc. | 0.01 | -0.11 | -91.74% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 12, 2026